Healthlinx Shareholders Approve Sale of OvPlex Dx to Mane Cancer Diagnostics
October 05, 2012
Healthlinx Shareholders Approve Sale of OvPlex Dx to Mane Cancer Diagnostics
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Mane Cancer Dx Requests Extension of Deadlines Related to Healthlinx OvPlex Deal
December 7, 2012 / ProteoMonitor - Healthlinx's OvPlex Deal with Mane Cancer Dx Expires as Mane Unable to Raise Needed Funds
January 11, 2013 / ProteoMonitor - UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor - Healthlinx Inks Deal to Sell OvPlex Dx to San Diego-Based Startup Mane Cancer Diagnostics
August 31, 2012 / ProteoMonitor - HealthLinx Says New OvPlex Algorithm Beats CA125 in Avoiding False Positives
July 6, 2012 / ProteoMonitor